Socrates was a classical Greek scholar who had a reputation for teaching by asking questions but not necessarily providing answers. Naming a randomized trial after him is tempting fate. You might just get what you ask for-questions but no clear answers!
The SOCRATES (SOluble guanylate Cyclase stimulatoR in heArT failurE Studies) programme set out to identify one or more preferred doses of vericiguat (Figure 1) , to take forward into major outcome trials for the treatment of recently re-compensated heart failure. 1 There were two component trials; one for left ventricular ejection fraction (LVEF) <45% (SOCRATES-REDUCED 2 ) and the other for LVEF >45% (SOCRATES-PRESERVED 3 ). The primary endpoint for both was the change in N-terminal pro brain natriuretic peptide (NT-proBNP); left atrial volume index was a co-primary endpoint in SOCRATES-PRESERVED. Neither study met its primary endpoint. In SOCRATES-REDUCED, titration to the highest dose of vericiguat, 10 mg/day, was associated with a fall in NT-proBNP, an increase in hypotensive episodes (although no difference in average blood pressure), a modest increase in LVEF, and numerically fewer hospitalizations for worsening heart failure. In SOCRATES-PRESERVED, no effect on NT-proBNP or left atrial volume index was observed at any dose, there was no increase in hypotensive episodes, no obvious effect on worsening heart failure, but a numerical increase in deaths with vericiguat. In one of many exploratory analyses, an improvement in quality of life was identified, largely driven by improved symptoms, amongst those titrated to the 10 mg dose of vericiguat. SOCRATES-PRESERVED was marred by some errors in randomization.
Is this the correct way to phenotype heart failure? These studies used a combination of a clinical diagnosis, evidence of congestion requiring administration of diuretics, LVEF, an elevated plasma NT-proBNP, and, if LVEF was >45%, left atrial dilatation to select patients and stratify them into component trials. These are robust diagnostic criteria for heart failure but do not conform to the three LVEF phenotypes proposed by recent ESC guidelines:
4 reduced (HFrEF), mid-range (HFmrEF), and preserved (HFpEF). In clinical practice, LVEF measured by echocardiography has considerable observer variability. This was a key driver for the introduction of HFmrEF. Using a single threshold value (i.e. 40%) to distinguish HFrEF from HFpEF will misclassify many patients because of measurement error. Having HFmrEF as a grey zone ensures that, in the future, fewer HFrEF patients will be misclassified as HFpEF, and vice versa, and that if a treatment is shown to be effective then it is clear for which phenotypes. HFmrEF may be uncommon; the first attempted clinical trial of this phenotype failed to enrol patients and was abandoned. 5 Pragmatically, if a treatment is shown to be effective for both HFrEF and HFpEF, then it might be assumed to be effective for HFmrEF. On the other hand, a study that included both HFmrEF and HFpEF would need to show that the treatment was effective in the subgroup with HFpEF before clinicians could be sure that it was not just effective for patients with milder degrees of LV systolic dysfunction, as in a recent study of spironolactone. 6 Of course, this all presupposes that LVEF is a useful way to phenotype heart failure. LVEF might just be a surrogate marker for other characteristics that are important determinants of outcome or treatment effect, including age, sex, the aetiology of ventricular dysfunction, the prevalence of atrial fibrillation and other co-morbidities, or NT-proBNP. We should not forget that the idea of using LVEF as an entry criterion for studies of heart failure is <30 years old.
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Is NT-proBNP a useful surrogate endpoint for Phase II studies in heart failure? NT-proBNP is the most powerful, simple, widely available prognostic marker in patients with chronic heart failure However, plasma concentrations of natriuretic peptides in patients with known heart failure are not strong predictors of an adverse prognosis when measured during the acute phase (e.g. the first 24 h) of decompensated heart failure. 9, 10 This may reflect a strength rather than a weakness. If a biomarker measured during the acute phase predicts longer term prognosis then either it is a poor measure of decompensation or it is unresponsive to change and of little use in monitoring. If NT-proBNP is measured serially, then the last measured value carries most of the prognostic information. 11, 12 Treatments that improve prognosis, including angiotensin-converting enzyme inhibitors, mineralocorticoid antagonists, angiotensin receptor neprilysin inhibitors, cardiac resynchronization therapy, and, more controversially, beta-blockers, 13 all reduce NT-proBNP and improve prognosis. Diuretics are possibly the most effective agents for reducing NT-proBNP, 14 and there is little doubt that diuretics are life-saving in severely congested patients even if evidence from randomised trials is lacking. If NT-proBNP is a marker of congestion, a pathophysiology driven by both cardiac and renal dysfunction, and congestion is a marker of prognosis, this provides a rationale for, and limitation of, using it as a surrogate endpoint in clinical trials. In decompensated heart failure, an acute intervention might temporarily relieve congestion and transiently reduce NT-proBNP. However, if the effect does not persist, then an improvement in longer term prognosis should not be expected. On the other hand, an intervention that causes a persistent reduction in NT-proBNP should lead to improved prognosis. Whether this hypothesis is true requires the test of time and many more prospective confirmatory trials. Whether other biomarkers, such as troponin, can provide supple mentary information also requires investigation. Clearly, the published studies of vericiguat do not provide a strong argument for progressing to large outcome trials, although a large trial in patients with HFrEF has been initiated (VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) (https://clinicaltrials.gov/ct2/show/NCT02861534? term=VICTORIA&rank=3)). On the other hand, they do offer some evidence of an effect. How then to proceed? The first issue is to focus on the ultimate treatment goals, which should be important to either the patient or the clinician or society, and preferably all three. These include improvement (or prevention of worsening) in symptoms and well-being, reductions in disability and morbidity, maintenance of independence, or prolongation of life. Alternatively, an intervention that simplifies management and/or reduces costs might be worthwhile. The treatment goals will determine the target population and the size and duration of the next study. As most patients with heart failure are already receiving many medications, the treatment should either have a substantial benefit, in order to convince physicians and patients to take an additional therapy, or simplify management, for instance by making other treatments redundant. The most important therapeutic outcome will vary according to context and individual patient. For a patient with severe unremitting symptoms, the most important outcome may not be survival but symptom relief. Paradoxically, it is probably the patient with heart failure who has fewer symptoms and a better prognosis for whom longevity is the most important target. Large trials are required to demonstrate safety, but, unless a treatment is effective, safety is clinically irrelevant since only effective treatments should be used.
If a treatment has a useful and consistent effect on symptoms and functional capacity, then some form of crossover trial should be considered, since using the patient as their own control greatly increases statistical power. Such a trial should require <100 patients. If it requires more, then the effect is unlikely to be of great clinical utility. Of course, enrolling the right patient is critical; you can only fix a problem if it exists. Although symptoms are often what provoke the patient to seek medical help, neither guidelines nor recent clinical trials pay great attention to improving them. Indeed, pride of place for improving symptoms is given to diuretics. This raises the question of what the comparator should be for trials investigating the effects of treatments on symptoms; should it be placebo, an increased dose of diuretic, or both? This will increase the complexity of the study design but, for an effective agent, would ensure clinical relevance. Several Vericiguat is a soluble guanylate cyclase (sGC) stimulator designed to amplify the effects of nitric oxide (NO) on its natural intracellular receptor, soluble guanylate cyclase. This increases production of cyclic guanosine monophosphate (cGMP). Activation of protein kinase G (PKG) is in turn thought to mediate many of the acute cardiovascular effects of cGMP. cGMP directly or indirectly may also alter expression of transforming growth factor (TGF)-b which might be responsible for longer term effects on cardiovascular structure. sGC activators are also being developed that may increase the responsiveness of oxidised sGC to NO or increase autonomous production. sGC has an iron containing heme component which, when oxidised, is much less responsive to NO. Oxidation may occur due to disease or to prolonged stimulation by NO. agents have improved symptoms of HFpEF in clinical trials and yet these have not caused guidelines to recommend their use. 15 It is important that guidelines on heart failure are not just about procrastinating death but rather provide recommendations to promote the broader well-being of patients. There is a view that for heart failure, health services, unlike for many other diseases, are less willing to pay for treatments that improve only symptoms but not prognosis. Industry is required to charge a premium price for new treatments because they have to get a return on investment within a relatively short space of time. One solution is longer patent protection on new treatments, akin to that for artists who get at least 70 years from first performance. 16 Long patents would allow companies to get a return on their investment through volume and duration of sales rather than high prices. Health systems might pay roughly the same amount but over a longer period of time.
If the focus remains on reducing morbidity and mortality, then larger studies will be required. Most clinical trials that have revolutionized care enrolled fewer than 3000 patients and most were stopped early because of greater than anticipated benefit ( Figure 2) . If a treatment is highly effective and likely to be cost-effective then very large trials are unnecessary. With the increasing cost and complexity of delivering care, the practical clinical value of demonstrating small benefits becomes questionable and potentially unaffordable. Recently, the PARADIGM-HF study demonstrated the superiority of sacubitril-valsartan over enalapril in >8000 patients, but sacubitril-valsartan only received a class IB recommendation in guidelines; to gain a class IA recommendation requires a confirmatory trial in a similar population, which seems unlikely to happen.
We think Socrates would have been flattered to know that his memory had been honoured by having a clinical trial named after him >2000 years after his death. To quote Earl C. Kelley: 17 ' We have not succeeded in answering all our problems. The answers we have found only serve to raise a whole set of new questions. In some ways we feel we are as confused as ever, but we believe we are confused on a higher level and about more important things.'
